Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in
a concentration-dependent manner. This review describes the extensive clinical …

Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in
phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for …

Historically, vitamin K antagonists have been the only class of oral anticoagulants available.
Despite our experience with warfarin over the past 60 years, its use is associated with …

Purpose The pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety,
and place in therapy of edoxaban for prevention of stroke in patients with nonvalvular atrial …

Background Edoxaban is an oral, once‐daily, direct factor Xa inhibitor under investigation
for stroke prevention in patients with atrial fibrillation and for treatment and secondary …

Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for
the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate …

Long-term anticoagulation treatment with warfarin has been associated with a number of
limitations in clinical practice and there is a need for more convenient long-term …

Vitamin K antagonists (VKAs) remain the standard therapy for anticoagulation in prevention
and treatment of venous thromboembolism (VTE) and for the prevention of stroke in atrial …

This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
study of a single ascending dose (SAD) and a multiple ascending dose (MAD) of the oral …

The primary objective of this study was to compare the safety of four fixed-dose regimens of
edoxaban with warfarin in patients with nonvalvular atrial fibrillation (AF). In this 12-week …